A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
NCT ID: NCT05763121
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1061 participants
INTERVENTIONAL
2023-01-30
2025-12-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600
Phase III Long-Term Extension Study With Dexpramipexole
NCT06388889
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04719832
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
NCT03170271
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo oral tablet taken twice a day
Placebo
oral administration of placebo tablet
150 mg BID
Dexpramipexole 150 mg oral tablet taken twice a day
Dexpramipexole Dihydrochloride
oral administration of dexpramipexole tablet
75 mg BID
Dexpramipexole 75 mg oral tablet taken twice a day
Dexpramipexole Dihydrochloride
oral administration of dexpramipexole tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexpramipexole Dihydrochloride
oral administration of dexpramipexole tablet
Placebo
oral administration of placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female ≥12 years of age at Screening Visit 1
Asthma-related criteria
3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1.
4. Treatment of asthma, participants must satisfy all the below (items a to c):
1. Participants who have received asthma controller medication with medium or high dose inhaled corticosteroids (ICS; ≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per Global Initiative for Asthma (GINA) 2021) on a regular basis for at least 12 months prior to Screening Visit 1.
2. Documented treatment with a stable dose of either medium or high dose ICS for at least 3 months prior to Screening Visit 1. The ICS may be contained within an ICS/LABA (long-acting β2 agonist) combination product. Daily oral corticosteroids are an allowed concomitant medication; participants on daily oral corticosteroids must be on a stable dose for 3 months before Screening Visit 1.
3. Use of one of more additional daily maintenance asthma controller medications according to standard practice of care is required. Use of a stable dose of any additional asthma controller medications must be documented for at least 3 months prior to Screening Visit 1.
5. Pre-bronchodilator forced expiratory volume (Pre-BD FEV₁) ≥40% and \<80% (\<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2.
6. Variable airflow obstruction documented with at least one of the following criteria:
1. Bronchodilator reversibility at Screening Visit 2, as evidenced by ≥12% and ≥200 mL improvement in FEV₁, 15 to 30 minutes following inhalation of 400 μg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to17). Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening period, at an unscheduled visit at least 7 days prior to baseline.
2. Bronchodilator reversibility, using the criteria above, documented in the past 24 months prior to Screening Visit 1.
3. Peak flow variation of ≥20% over a 2-week period, documented in the past 24 months prior to Screening Visit 1.
4. Airflow variability in clinic FEV₁ ≥20% between two consecutive clinic visits, documented in the past 24 months prior to Screening Visit 1.
5. Airway hyperresponsiveness (provocative concentration causing a 20% fall in FEV₁ of methacholine \<8 mg/mL) documented in the past past 24 months prior to Screening Visit 1.
7. ACQ-6 ≥1.5 at Screening Visit 2.
8. Documented history of at least two asthma exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral) within the past 12-month period prior to Screening Visit 1.
General medical history
9. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening Visit 2 and Baseline Visit.
10. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit:
1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive.
Or
2. Two protocol acceptable methods of contraception in tandem.
Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for ≥12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply:
3. Women \<50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range.
4. Women ≥50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
Exclusion Criteria
1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids) at any time from 4 weeks prior to Screening Visit.
Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening Visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status.
2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, hypereosinophilic syndrome, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis.
3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1.
4. For participants aged 12 to 17 years old, AEC of \<0.15x10⁹/L at Screening Visit 1.
Prohibited medications/procedures
5. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long-acting anti-IL-5) in the past 12 months.
6. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline Visit: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab.
7. Treatment with pramipexole (Mirapex®) within 30 days of Baseline Visit.
8. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1.
9. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the coming year.
General medical history
10. Weight \<40 kg at Screening Visit 2.
11. Current smoking within the 12 months prior to Screening Visit 1 or a smoking history of \>10 pack-years. Smoking includes tobacco, vaping, and/or marijuana use.
12. Known or suspected alcohol or drug abuse
13. Uncontrolled severe hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg prior to the Baseline Visit despite antihypertensive therapy.
14. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to the Baseline Visit.
15. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C.
16. A helminth parasitic infection diagnosed within 24 weeks prior to Screening Visit 1 that has not been treated with or has failed to respond to standard of care (SoC) therapy.
17. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements.
18. Known or suspected noncompliance with medication.
19. Unwillingness or inability to follow the procedures outlined in the protocol.
Clinical safety labs
20. Absolute neutrophil count (ANC) \<2.000x10⁹/L at Screening Visit 1 or Screening Visit 2.
21. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m² at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula for age ≥18 years at screening; using the Bedside Schwartz eGFR formula).
22. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart.
Cardiac safety
23. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%.
24. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit.
25. History of cardiac arrhythmia within 3 months prior to the Baseline Visit that is not controlled by medication or via ablation.
26. History of long QT syndrome.
27. Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at Screening Visit 2 or QTcF ≥480 ms for participants with bundle branch block.
28. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including heart rate \<45 beats per minute (bpm) or \>100 bpm.
Pregnancy/Lactation
29. Pregnant women or women breastfeeding
30. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
12 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Areteia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salman Siddiqui, MD
Role: PRINCIPAL_INVESTIGATOR
Imperial College Healthcare NHS Trust (via Imperial Consultants)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site 20001-374
Bakersfield, California, United States
Research Site 20001-440
La Palma, California, United States
Research Site 20001-062
Newport Beach, California, United States
Research Site 20001-043
Newport Beach, California, United States
Research Site 20001-380
Redding, California, United States
Research Site US-20001-488
San Diego, California, United States
Research Site 20001-003
West Covina, California, United States
Research Site 20001-419
Westminster, California, United States
Research Site 20001-048
Aventura, Florida, United States
Research Site 20001-005
Brandon, Florida, United States
Research Site 20001-051
Brandon, Florida, United States
Research Site 20001-029
Coral Gables, Florida, United States
Research Site 20001-350
Gainesville, Florida, United States
Research Site 20001-014
Green Acres, Florida, United States
Research Site 20001-054
Hialeah, Florida, United States
Research Site 20001-067
Hialeah, Florida, United States
Research Site 20001-020
Homestead, Florida, United States
Research Site 20001-015
Kissimmee, Florida, United States
Research Site 20001-002
Kissimmee, Florida, United States
Research Site 20001-086
Loxahatchee Groves, Florida, United States
Research Site 20001-066
Miami, Florida, United States
Research Site 20001-001
Miami, Florida, United States
Research Site 20001-059
Miami, Florida, United States
Research Site 20001-026
Miami, Florida, United States
Research Site 20001-065
Miami, Florida, United States
Research Site 20001-024
Miami, Florida, United States
Research Site 20001-069
St. Petersburg, Florida, United States
Research Site 20001-004
Tampa, Florida, United States
Research Site 20001-075
Augusta, Georgia, United States
Research Site 20001-018
Columbus, Georgia, United States
Research Site 20001-459
Sugar Hill, Georgia, United States
Research Site 20001-090
Berwyn, Illinois, United States
Research Site 20001-476
Chicago, Illinois, United States
Research Site 20001-358
Normal, Illinois, United States
Research Site 20001-135
River Forest, Illinois, United States
Research Site 20001-403
Skokie, Illinois, United States
Research Site 20001-036
Elwood, Indiana, United States
Research Site 20001-044
Evansville, Indiana, United States
Research Site 20001-021
Iowa City, Iowa, United States
Research Site 20001-019
Owensboro, Kentucky, United States
Research Site 20001-466
Baltimore, Maryland, United States
Research Site 20001-456
Takoma Park, Maryland, United States
Research Site 20001-055
White Marsh, Maryland, United States
Research Site 20001-468
Fall River, Massachusetts, United States
Research Site 20001-006
Flint, Michigan, United States
Research Site 20001-148
Flint, Michigan, United States
Research Site 20001-463
Rochester Hills, Michigan, United States
Research Site 20001-370
Chesterfield, Missouri, United States
Research Site 20001-074
Saint Charles, Missouri, United States
Research Site 20001-046
St Louis, Missouri, United States
Research Site 20001-409
Missoula, Montana, United States
Research Site 20001-486
Henderson, Nevada, United States
Research Site 20001-473
Las Vegas, Nevada, United States
Research Site 20001-471
Highland Park, New Jersey, United States
Research Site 20001-457
Jersey City, New Jersey, United States
Research Site 20001-420
New Brunswick, New Jersey, United States
Research Site 20001-050
East Amherst, New York, United States
Research Site 20001-047
Hawthorne, New York, United States
Research Site 20001-422
Rochester, New York, United States
Research Site 20001-368
The Bronx, New York, United States
Research Site 20001-408
Charlotte, North Carolina, United States
Research Site 20001-039
Gastonia, North Carolina, United States
Research Site 20001-435
Greenville, North Carolina, United States
Research Site 20001-382
Raleigh, North Carolina, United States
Research Site 20001-034
Cincinnati, Ohio, United States
Research Site 20001-013
Cincinnati, Ohio, United States
Research Site 20001-017
Dayton, Ohio, United States
Research Site 20001-063
Toledo, Ohio, United States
Research Site 20001-038
Edmond, Oklahoma, United States
Research Site 20001-079
Oklahoma City, Oklahoma, United States
Research Site 20001-395
Hershey, Pennsylvania, United States
Research Site 20001-032
Columbia, South Carolina, United States
Research Site 20001-025
Greenville, South Carolina, United States
Research Site 20001-073
Spartanburg, South Carolina, United States
Research Site 20001-438
Dickson, Tennessee, United States
Research Site 20001-068
Amarillo, Texas, United States
Research Site 20001-023
Dallas, Texas, United States
Research Site 20001-028
Dallas, Texas, United States
Research Site 20001-064
Houston, Texas, United States
Research Site 20001-085
Houston, Texas, United States
Research Site 20001-478
Plano, Texas, United States
Research Site 20001-072
The Woodlands, Texas, United States
Research Site 20001-258
Murray, Utah, United States
Research Site 20001-477
Salt Lake City, Utah, United States
Research Site 20001-340
Burke, Virginia, United States
Research Site 20001-479
Vienna, Virginia, United States
Research Site 20001-480
Barboursville, West Virginia, United States
Research Site 20001-433
La Crosse, Wisconsin, United States
Research Site 20001-057
Madison, Wisconsin, United States
Research Site 20054-054
Buenos Aires, , Argentina
Research Site -20054-021
Buenos Aires, , Argentina
Research Site 20054-023
Buenos Aires, , Argentina
Research Site 20054-011
Buenos Aires, , Argentina
Research Site 20054-017
Buenos Aires, , Argentina
Research Site 20054-015
Buenos Aires, , Argentina
Research Site 20054-022
Buenos Aires, , Argentina
Research Site 20054-024
Buenos Aires, , Argentina
Research Site 20054-008
Buenos Aires, , Argentina
Research Site 20054-005
Córdoba, , Argentina
Research Site 20054-019
Mendoza, , Argentina
Research Site 20054-016
Mendoza, , Argentina
Research Site 20054-010
Mendoza, , Argentina
Research Site 20054-013
Rosario, , Argentina
Research Site 20054-002
San Miguel de Tucumán, , Argentina
Research Site 20054-020
San Miguel de Tucumán, , Argentina
Research Site 20055-012
Porto Alegre, Rio Grande do Sul, Brazil
Research Site 20055-004
Porto Alegre, Rio Grande do Sul, Brazil
Research Site 20055-014
Ribeirão Preto, São Paulo, Brazil
Research Site 20055-009
Santos, São Paulo, Brazil
Research Site 20055-001
São Bernardo do Campo, São Paulo, Brazil
Research Site 20055-002
Sorocaba, São Paulo, Brazil
Research Site 20055-007
Blumenau, , Brazil
Research Site 20055-011
Campo Largo, , Brazil
Research Site 20055-010
Porto Alegre, , Brazil
Research Site 20055-005
Santo André, , Brazil
Research Site 20055-003
São Paulo, , Brazil
Research Site 20055-008
São Paulo, , Brazil
Research Site 20359-017
Dimitrovgrad, , Bulgaria
Research Site 20359-022
Kozloduy, , Bulgaria
Research Site 20359-027
Lovech, , Bulgaria
Research Site 20359-008
Montana, , Bulgaria
Research Site 20359-029
Montana, , Bulgaria
Research Site 20359-010
Pernik, , Bulgaria
Research Site 20359-023
Pleven, , Bulgaria
Research Site 20359-026
Plovdiv, , Bulgaria
Research Site 20359-024
Plovdiv, , Bulgaria
Research Site 20359-005
Rousse, , Bulgaria
Research Site 20359-009
Sliven, , Bulgaria
Research Site 20359-033
Sliven, , Bulgaria
Research Site 20359-025
Smolyan, , Bulgaria
Research Site 20359-014
Sofia, , Bulgaria
Research Site 20359-030
Sofia, , Bulgaria
Research Site 20359-020
Sofia, , Bulgaria
Research Site 20359-006
Sofia, , Bulgaria
Research Site 20359-015
Sofia, , Bulgaria
Research Site 20359-003
Stara Zagora, , Bulgaria
Research Site 20359-019
Stara Zagora, , Bulgaria
Research Site 20359-021
Velingrad, , Bulgaria
Research Site 20359-016
Vidin, , Bulgaria
Research Site 20011-011
Vancouver, British Columbia, Canada
Research Site 20011-019
Winnipeg, Manitoba, Canada
Research Site 20011-016
Ajax, Ontario, Canada
Research Site 20011-004
Ajax, Ontario, Canada
Research Site 20011-010
Burlington, Ontario, Canada
Research Site 20011-001
Windsor, Ontario, Canada
Research Site 20011-018
Montreal, Quebec, Canada
Research Site 20011-022
Québec, Quebec, Canada
Research Site 20011-020
Trois-Rivières, Quebec, Canada
Research Site 20011-024
Guelph, , Canada
Research Site 20086-071
Jilin, Jilin, China
Research Site 20086-001
Taizhou, Zhejang, China
Research Site 20086-011
Baoding, , China
Research Site 20086-037
Beijing, , China
Research Site 20086-056
Beijing, , China
Research Site 20086-012
Beijing, , China
Research Site 20086-036
Beijing, , China
Research Site 20086-057
Beijing, , China
Research Site 20086-068
Beijing, , China
Research Site 20086-002
Beijing, , China
Research Site 20086-029
Beijing, , China
Research Site 20086-076
Chengdu, , China
Research Site 20086-072
Guandong, , China
Research Site 20086-060
Guangdong, , China
Research Site 20086-075
Guangxi, , China
Research Site 20086-069
Guangzhou, , China
Research Site 20086-039
Guizhou, , China
Research Site 20086-050
Hangzhou, , China
Research Site 20086-051
Hangzhou, , China
Research Site 20086-059
Hangzhou, , China
Research Site 20086-007
Hangzhou, , China
Research Site 20086-022
Jinan, , China
Research Site 20086-048
Luoyang, , China
Research Site 20086-030
Nanchang, , China
Research Site 20086-009
Nanchang, , China
Research Site 20086-040
Ningbo, , China
Research Site 20086-021
Pudong, , China
Research Site 20086-019
Qingdao, , China
Research Site 20086-061
Shanghai, , China
Research Site 20086-063
Shanghai, , China
Research Site 20086-052
Shanghai, , China
Research Site 20086-041
Shanghai, , China
Research Site 20086-053
Shenyang, , China
Research Site 20086-064
Taiyuan, , China
Research Site 20086-032
Weifang, , China
Research Site 20086-032
Weifang, , China
Research Site 20086-066
Wuxi, , China
Research Site 20086-017
Zhejiang, , China
Research Site 20057-008
Barranquilla, , Colombia
Research Site 20057-006
Bogotá, , Colombia
Research Site 20057-007
Ibagué, , Colombia
Research Site 20057-009
Santander, , Colombia
Research Site 20057-001
Zipaquirá, , Colombia
Research Site 20995-007
Batumi, , Georgia
Research Site 20995-001
Kutaisi, , Georgia
Research Site 20995-005
Tbilisi, , Georgia
Research Site 20995-010
Tbilisi, , Georgia
Research Site 20995-006
Tbilisi, , Georgia
Research Site 20995-002
Tbilisi, , Georgia
Research Site 20995-003
Tbilisi, , Georgia
Research Site 20995-004
Tbilisi, , Georgia
Research Site 20995-009
Tbilisi, , Georgia
Research Site 20995-008
Tbilisi, , Georgia
Research Site 20081-080
Asahikawa, , Japan
Research Site 20081-046
Fukuoka, , Japan
Research Site 20081-003
Fukuoka, , Japan
Research Site 20081-044
Fukuoka, , Japan
Research Site 20081-025
Fukuoka, , Japan
Research Site 20081-015
Gifu, , Japan
Research Site 20081-077
Himeji, , Japan
Research Site 20081-078
Hiroshima, , Japan
Research Site 20081-071
Hokkaido, , Japan
Research Site 20081-042
Ibaraki, , Japan
Research Site 20081-069
Isehara, , Japan
Research Site 20081-050
Kagoshima, , Japan
Research Site 20081-079
Kobe, , Japan
Research Site 20081-039
Kobe, , Japan
Research Site 20081-072
Kochi, , Japan
Research Site 20081-052
Kochi, , Japan
Research Site 20081-090
Maebashi, , Japan
Research Site 20081-030
Matsusaka, , Japan
Research Site 20081-083
Miura, , Japan
Research Site 20081-021
Nagoya, , Japan
Research Site 20081-073
Nagoya, , Japan
Research Site 20081-056
Niigata, , Japan
Research Site 20081-037
Okayama, , Japan
Research Site 20081-088
Ono, , Japan
Research Site 20081-086
Osaka, , Japan
Research Site 20081-024
Osaka, , Japan
Research Site 20081-068
Osaka, , Japan
Research Site 20081-041
Saga, , Japan
Research Site 20081-076
Saitama, , Japan
Research Site 20081-009
Shibuya-ku, , Japan
Research Site 20081-032
Shimane, , Japan
Research Site 20081-031
Shizuoka, , Japan
Research Site 20081-061
Shizuoka, , Japan
Research Site 20081-076
Tarumi, , Japan
Research Site 20081-034
Tokyo, , Japan
Research Site 20081-028
Tokyo, , Japan
Research Site 20081-023
Tokyo, , Japan
Research Site 20081-026
Tokyo, , Japan
Research Site 20081-066
Tokyo, , Japan
Research Site 20081-019
Tokyo, , Japan
Research Site 20081-074
Tokyo, , Japan
Research Site 20081-065
Tokyo, , Japan
Research Site 20081-029
Tokyo, , Japan
Research Site 20081-062
Toyama, , Japan
Research Site 20081-038
Toyama, , Japan
Research Site 20081-049
Tsuchiura, , Japan
Research Site 20081-016
Yamaguchi, , Japan
Research Site 20081-011
Yokohama, , Japan
Research Site 20081-051
Yokohama, , Japan
Research Site 20081-087
Yonago, , Japan
Research Site 20081-043
Yoshida, , Japan
Research Site 20961-007
Aïn Ouzaïn, , Lebanon
Research Site 20961-003
Beirut, , Lebanon
Research Site 20961-004
Beirut, , Lebanon
Research Site 20961-009
Beirut, , Lebanon
Research Site 20961-010
Beirut, , Lebanon
Research Site 20961-012
Beirut, , Lebanon
Research Site 20961-005
Tripoli, , Lebanon
Research Site 20052-011
Benito Juárez, , Mexico
Research Site 20052-008
Córdoba, , Mexico
Research Site 20052-035
Cuernavaca, , Mexico
Research Site 20052-002
Guadalajara, , Mexico
Research Site 20052-034
Guadalajara, , Mexico
Research Site 20052-013
Mérida, , Mexico
Research Site 20052-004
Mérida, , Mexico
Research Site 20052-012
San Juan del Río, , Mexico
Research Site 20052-037
San Nicolás de los Garza, , Mexico
Research Site 20052-006
Veracruz, , Mexico
Research Site 20052-009
Zapopan, , Mexico
Research Site 20389-006
Shtip, , North Macedonia
Research Site 20389-003
Skopje, , North Macedonia
Research Site 20389-004
Skopje, , North Macedonia
Research Site 20389-007
Skopje, , North Macedonia
Research Site 20389-005
Strumica, , North Macedonia
Research Site 20389-001
Veles, , North Macedonia
Research Site 20051-009
Lima, , Peru
Researcdh Site 20051-014
Lima, , Peru
Research Site 20051-012
Lima, , Peru
Research Site 20051-013
Lima, , Peru
Research Site 20051-030
Lima, , Peru
Research Site 20051-003
Lima, , Peru
Research Site 20051-007
Lima, , Peru
Research Site 20051-006
Lima, , Peru
Research Site 20051-010
Lima, , Peru
Research Site 20051-001
Lima, , Peru
Research Site20051-002
Lima, , Peru
Research Site 20051-008
Piura, , Peru
Research Site 20048-001
Będzin, , Poland
Research Site 20048-018
Bialystok, , Poland
Research Site 20048-032
Bialystok, , Poland
Research Site 20048-006
Giżycko, , Poland
Research Site 20048-021
Katowice, , Poland
Research Site 20048-002
Katowice, , Poland
Research Site 20048-036
Kielce, , Poland
Research Site 20048-027
Krakow, , Poland
Research Site 20048-033
Krakow, , Poland
Research Site 20048-008
Krakow, , Poland
Research Site 20048-040
Krakow, , Poland
Research Site 20048-005
Lodz, , Poland
Research Site 20048-009
Lodz, , Poland
Research Site 20048-015
Lodz, , Poland
Research Site 20048-022
Lublin, , Poland
Research Site 20048-024
Maków Podhalański, , Poland
Research Site 20048-031
Ostrowiec Świętokrzyski, , Poland
Research Site 20048-010
Piaseczno, , Poland
Research Site 20048-028
Poznan, , Poland
Research Site 20048-016
Poznan, , Poland
Research Site 20048-039
Rzeszów, , Poland
Research Site 20048-014
Skierniewice, , Poland
Research Site 20048-037
Torun, , Poland
Research Site 20048-012
Trzebnica, , Poland
Research Site 20048-034
Warsaw, , Poland
Research Site 20048-019
Wroclaw, , Poland
Research Site 20048-029
Wroclaw, , Poland
Research Site 20787-365
Guaynabo, , Puerto Rico
Research Site 20787-390
Ponce, , Puerto Rico
Research Site 20040-004
Brasov, Brașov County, Romania
Research Site 20040-006
Cluj-Napoca, Cluj, Romania
Research Site 20040-008
Bragadiru, , Romania
Research Site 20040-002
Brasov, , Romania
Research Site 20040-004
Brasov, , Romania
Research Site 20040-011
Timișoara, , Romania
Research Site 20381-002
Belgrade, , Serbia
Research Site 20381-007
Belgrade, , Serbia
Research Site 20381-010
Belgrade, , Serbia
Research Site 20381-012
Belgrade, , Serbia
Research Site 20381-005
Belgrade, , Serbia
Research Site 20381-006
Belgrade, , Serbia
Research Site 20381-008
Kamenitz, , Serbia
Research Site 20381-001
Kragujevac, , Serbia
Research Site 20381-004
Niš, , Serbia
Research Site 20381-009
Novi Sad, , Serbia
Research Site 20381-011
Užice, , Serbia
Research Site 20381-003
Valjevo, , Serbia
Research Site 20082-003
Anyang, , South Korea
Research Site 20082-007
Busan, , South Korea
Research Site 20082-009
Daegu, , South Korea
Research Site 20381-009
Incheon, , South Korea
Research Site 20082-006
Jeonju, , South Korea
Research Site 20082-013
Seoul, , South Korea
Research Site 20082-019
Seoul, , South Korea
Research Site 20082-008
Seoul, , South Korea
Research Site 20082-004
Seoul, , South Korea
Research Site 20082-014
Seoul, , South Korea
Research Site 20082-011
Seoul, , South Korea
Research Site 20082-010
Suwon, , South Korea
Research Site 20380-002
Chernivtsi, , Ukraine
Research Site 20380-021
Chernivtsi, , Ukraine
Research Site 20380-017
Ivano-Frankivsk, , Ukraine
Research Site 20380-004
Ivano-Frankivsk, , Ukraine
Research Site 20380-009
Ivano-Frankivsk, , Ukraine
Research Site 20380-014
Ivano-Frankivsk, , Ukraine
Research Site 20380-015
Kyiv, , Ukraine
Research Site 20380-019
Kyiv, , Ukraine
Research Site 20380-007
Kyiv, , Ukraine
Research Site 20380-010
Kyiv, , Ukraine
Research Site 20380-012
Kyiv, , Ukraine
Research Site 20380-011
Kyiv, , Ukraine
Research Site 20380-013
Kyiv, , Ukraine
Research Site 20380-018
Kyiv, , Ukraine
Research Site 20380-016
Lutsk, , Ukraine
Research Site 20380-001
Ternopil, , Ukraine
Research Site 20380-003
Vinnytsia, , Ukraine
Research Site 20380-020
Vinnytsia, , Ukraine
Research Site 20380-022
Vinnytsia, , Ukraine
Research Site 20380-008
Vinnytsia, , Ukraine
Research Site 20380-005
Zhytomyr, , Ukraine
Research Site 20044-001
Manchester, Greater Manchester, United Kingdom
Research Site 20044-033
Manchester, Greater Manchester, United Kingdom
Research Site 20044-046
Manchester, Greater Manchester, United Kingdom
Research Site 20044-013
Manchester, Greater Manchester, United Kingdom
Research Site 20044-008
Salford, Greater Manchester, United Kingdom
Research Site 20044-010
Altrincham, , United Kingdom
Research Site 20044-079
Bedford, , United Kingdom
Research Site 20044-018
Bellshill, , United Kingdom
Research Site 20044-083
Birmingham, , United Kingdom
Research Site 20044-021
Birmingham, , United Kingdom
Research Site 20044-077
Bollington, , United Kingdom
Research Site 20044-017
Chorley, , United Kingdom
Research Site 20044-022
Enfield, , United Kingdom
Research Site 20044-019
Liverpool, , United Kingdom
Research Site 20044-084
London, , United Kingdom
Research Site 20044-081
London, , United Kingdom
Research Site 20044-036
London, , United Kingdom
Research Site 20044-042
London, , United Kingdom
Research Site 20044-020
Manchester, , United Kingdom
Research Site 20044-031
Manchester, , United Kingdom
Research Site 20044-032
Manchester, , United Kingdom
Research Site 20044-009
Manchester, , United Kingdom
Research Site 20044-005
Manchester, , United Kingdom
Research Site 20044-030
Manchester, , United Kingdom
Research Site 20044-012
Manchester, , United Kingdom
Research Site 20044-004
Manchester, , United Kingdom
Research Site 20044-082
Nottingham, , United Kingdom
Research Site 20044-024
Preston, , United Kingdom
Research Site 20044-026
Rochdale, , United Kingdom
Research Site 20044-029
Stockport, , United Kingdom
Research Site 20044-034
Stockport, , United Kingdom
Research Site 20044-078
Wythenshawe, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-003004-33
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2023049491
Identifier Type: REGISTRY
Identifier Source: secondary_id
AR-DEX-22-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.